Overview

The Impact of Thymosin α-1 on the Efficacy of Concurrent Chemoradiotherapy Followed by Immunotherpay Consolidation for Locally Advanced NSCLC

Status:
Recruiting

Trial end date:
2026-08-01

Target enrollment:

Participant gender:

Summary

This prospective phase II randomized study is to determine the impact of thymosin alpha-1 on the concurrent chemoradiotherpay followed by immunotherapy consolidation in patients with locally advanced NSCLC by assessing the survival outcomes, treatment responses and toxicities.

Phase:

Phase 2

Details

Lead Sponsor:

Sun Yat-sen University

Treatments:

Albumin-Bound Paclitaxel
Cisplatin
Paclitaxel
Thymalfasin
Tislelizumab